"Allergan plc NYSE AGN httpstudio.financialcontent.comprnewsPageQuoteTickerAGN today announced that the CoolSculpting treatment is the first and only nonsurgical fat reduction technology to be FDAcleared for improved appearance of lax tissue in conjunction with submental fat or double chin treatments.  CoolSculpting for the double chin is already clinically proven to reduce fat up to  percent in the treated area after one treatment. Allergan is committed to advancing innovation for CoolSculpting to meet the needs of patients seeking noninvasive aesthetic treatments said David Nicholson Chief Research and Development Officer at Allergan. A  American Society for Dermatologic Surgery ASDS survey revealed that  percent of patients are bothered by excess fat under the chin. We are pleased this patient concern can successfully be addressed by CoolSculpting through a noninvasive approach and furthermore improve the appearance of lax tissue in the treated area. An week clinical study of CoolSculpting in submental fat treatment found that  percent of patients showed improved appearance of lax tissue and  percent of patients reported their chin looked more toned following treatment. In my own patients I have noticed the improved appearance of lax tissue when using the CoolMini applicator for the CoolSculpting system to treat the submental area said Jeffrey S. Dover MD FRCPC CoDirector of SkinCare Physicians of Chestnut Hill Mass. It is great to see the company invest to validate this and secure the FDA clearance. CoolSculpting is available through a network of CoolSculpting Centers worldwide. Dermatologists plastic surgeons and aesthetic specialists that offer CoolSculpting can be found at  http  References  Data On File Allergan Inc. Safety and Efficacy of Cryolipolysis for NonInvasive Reduction of Submental Fat   ASDS Consumer Survey   Data on File Allergan Inc. Study to Evaluate NonInvasive Subcutaneous Fat Reduction in the Submental Area Using Cryolipolysis  About the CoolSculpting Treatment CoolSculpting is a nonsurgical clinically proven treatment that selectively reduces unwanted fat using a patented cooling technology. Cleared by the FDA CoolSculpting works by gently cooling targeted fat cells in the body to induce a natural controlled elimination of fat cells without affecting surrounding tissue and the treated fat cells are gone for good. Millions of CoolSculpting treatments have been performed in more than  countries. CoolSculpting is available through a network of CoolSculpting Centers worldwide. Dermatologists plastic surgeons and aesthetic specialists that offer CoolSculpting can be found at  https_fG_GGkiRxEaLmhqmanWVMeVXRrTcVRxzskvI_VlsLjWXqMgLlzXlWI. In the U.S. the CoolSculpting procedure is FDAcleared for the treatment of visible fat bulges in the submental area thigh abdomen and flank along with bra fat back fat underneath the buttocks also known as banana roll and upper arm. It is also FDAcleared to affect the appearance of lax tissue with submental area treatments. During the procedure you may experience sensations of pulling tugging mild pinching intense cold tingling stinging aching and cramping at the treatment site. These sensations subside as the area becomes numb. Following the procedure typical side effects include temporary redness swelling blanching bruising firmness tingling stinging tenderness cramping aching itching or skin sensitivity and sensation of fullness in the back of the throat after submental area treatment. Rare side effects may also occur. The CoolSculpting procedure is not for everyone. You should not have the CoolSculpting procedure if you suffer from cryoglobulinemia cold agglutinin disease or paroxysmal cold hemoglobinuria. The CoolSculpting procedure is not a treatment for obesity. Please see full Important Safety Information http_Patient_Safety_Info_proof.pdf for additional information. Be sure to follow CoolSculpting on Facebook https Twitter https Pinterest https_syBwQunMraQE_fyaluRaYxVezzwZGYWSciNADysQauWYhgaYkG_sIwp_TzIAMmkVFxJreesSBlqtBs and YouTube https About Allergan plc Allergan plc NYSE AGN httpstudio.financialcontent.comprnewsPageQuoteTickerAGN headquartered in Dublin Ireland is a bold global pharmaceutical company and a leader in a new industry model  Growth Pharma. Allergan is focused on developing manufacturing and commercializing branded pharmaceutical device biologic surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and bestinclass products for the central nervous system eye care medical aesthetics and dermatology gastroenterology womens health urology and antiinfective therapeutic categories. Allergan is an industry leader in Open Science a model of research and development which defines our approach to identifying and developing gamechanging ideas and innovation for better patient care. With this approach Allergan has built one of the broadest development pipelines in the pharmaceutical industry with  midtolate stage pipeline programs currently in development. Allergans success is powered by our more than  global colleagues commitment to being Bold for Life. Together we build bridges power ideas act fast and drive results for our customers and patients around the world by always doing what is right. With commercial operations in approximately  countries Allergan is committed to working with physicians healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer healthier lives every day. For more information visit Allergans website at  http ForwardLooking Statement  Statements contained in this press release that refer to future events or other nonhistorical facts are forwardlooking statements that reflect Allergans current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergans current expectations depending upon a number of factors affecting Allergans business. These factors include among others the difficulty of predicting the timing or outcome of FDA approvals or actions if any the impact of competitive products and pricing market acceptance of and continued demand for Allergans products the impact of uncertainty around timing of generic entry related to key products including RESTASIS on our financial results uncertainty associated with financial projections projected cost reductions projected synergies restructurings increased costs and adverse tax consequences difficulties or delays in manufacturing and other risks and uncertainties detailed in Allergans periodic public filings with the Securities and Exchange Commission including but not limited to Allergans Annual Report on Form K for the year ended December   and Allergans Quarterly Report on Form Q for the period ended September  . Except as expressly required by law Allergan disclaims any intent or obligation to update these forwardlooking statements. ICA CONTACTS Allergan Investors Daphne Karydas   Media Mark Marmur   Marlo Rodman   SOURCE Allergan plc Related Links http"